Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Molecular characterization of melanoma cases in denmark suspected of genetic predisposition.

  • Karin A W Wadt
  • Lauren G Aoude
  • Lotte Krogh
  • Lone Sunde
  • Anders Bojesen
  • Karen Grønskov
  • Nine Wartacz
  • Jakob Ek
  • Morten Tolstrup-Andersen
  • Mette Klarskov-Andersen
  • Åke Borg
  • Steffen Heegaard
  • Jens F Kiilgaard
  • Thomas V O Hansen
  • Kerenaftali Klein
  • Göran B Jönsson
  • Krzysztof T Drzewiecki
  • Morten Dunø
  • Nicholas K Hayward
  • Anne-Marie Gerdes
Publishing year: 2015
Language: English
Publication/Series: PLoS ONE
Volume: 10
Issue: 3
Document type: Journal article
Publisher: Public Library of Science

Abstract english

Both environmental and host factors influence risk of cutaneous melanoma (CM), and worldwide, the incidence varies depending on constitutional determinants of skin type and pigmentation, latitude, and patterns of sun exposure. We performed genetic analysis of CDKN2A, CDK4, BAP1, MC1R, and MITFp.E318K in Danish high-risk melanoma cases and found CDKN2A germline mutations in 11.3% of CM families with three or more affected individuals, including four previously undescribed mutations. Rare mutations were also seen in CDK4 and BAP1, while MC1R variants were common, occurring at more than twice the frequency compared to Danish controls. The MITF p.E318K variant similarly occurred at an approximately three-fold higher frequency in melanoma cases than controls. To conclude, we propose that mutation screening of CDKN2A and CDK4 in Denmark should predominantly be performed in families with at least 3 cases of CM. In addition, we recommend that testing of BAP1 should not be conducted routinely in CM families but should be reserved for families with CM and uveal melanoma, or mesothelioma.


  • Cancer and Oncology


  • ISSN: 1932-6203
Åke Borg
Åke Borg
E-mail: ake [dot] borg [at] med [dot] lu [dot] se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2


Project manager

Familial Breast Cancer



Oncology and Pathology, MV

MV 404 C21C2